Previous 10 | Next 10 |
CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report fourth quarter and full year 2019 financial results after market ...
AbbVie (NYSE: ABBV ) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket. More news on: AbbVie Inc., Alkermes plc, BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Expectations can be irrational and still have power – that’s about the only reason I can see for why Neurocrine ( NBIX ) shares were as weak as they were coming out of the company’s JPMorgan Healthcare Conference presentation. Investors went into this conference with inf...
Audentes Therapeutics (NASDAQ: BOLD ) +105% as Astellas Pharma to buy Audentes Therapeutics for $60/share. More news on: Audentes Therapeutics, Inc., ViewRay, Inc., uniQure N.V., Stocks on the move, Read more ...
My expectations for Neurocrine Biosciences ( NBIX ) have been somewhat restrained for 2019, as this biotech didn’t have a lot of clinical updates on the docket and I thought the Street had largely adjusted to the stronger-than-expected Ingrezza launch trajectory. The shares have perke...
Neurocrine's Ingrezza continues tardive dyskinesia dominance Neurocrine Biosciences ( NBIX ) continues to impress with Ingrezza's tardive dyskinesia launch, with the drug securing nearly $200M in revenue for Q3 '19: Figure 2: Ingrezza marches towards blockbuster status (> $250M/q...
Continuing with the series of articles on gene therapy, this article will discuss the various delivery methods for gene therapies with a focus on viral vectors. What is transgene? A transgene is a new therapeutic DNA segment that is to be inserted into the host cell. In addition to the g...
Voyager Therapeutics, Inc (VYGR) Q3 2019 Results Conference Call November 06, 2019 08:00 AM ET Company Participants Vasilis Kariolis - Assistant Controller Andre Turenne - President and Chief Executive Officer Omar Khwaja - Chief Medical Officer and Head of R&D Matt Ottmer ...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
Image source: The Motley Fool. Voyager Therapeutics, Inc. (NASDAQ: VYGR) Q3 2019 Earnings Call Nov 6, 2019 , 8:00 a.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...